Fesoterodine Fumarate Tablet, Extended Release
Product Images NDC 67877-064

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Fesoterodine Fumarate (NDC 67877-064). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ascend Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fesoterodine-4mg-1 (Fesoterodine 4mg 1)

Fesoterodine Fumarate Extended-release Tablets 4 mg film-coated tablets in a 30-tablet package. Label shows the drug is manufactured by Alkem Laboratories Ltd., India, and distributed by Ascend Laboratories, LLC. It includes storage instructions, a barcode, and instructions for pharmacists to dispense with patient information leaflet.*

FDA Label Image

Fesoterodine-8mg-1 (Fesoterodine 8mg 1)

Label for Fesoterodine Fumarate 8 mg extended-release tablets, oral dosage form, containing 30 tablets per package. The label displays the drug name, strength, and tablet count, with instructions for pharmacists to dispense with a patient information leaflet. Manufactured by Alkem Laboratories Ltd., India, and distributed by Ascend Laboratories, LLC. Includes storage instructions and a barcode.*

FDA Label Image

Fesoterodine-fig1.jpg (Fesoterodine Fig1)

A line graph titled 'Change in Number of Micturitions per 24 h (Study 1)' showing mean changes from baseline in number of micturitions over 12 weeks. Three lines represent placebo, Fesoterodine Fumarate ER 4 mg, and Fesoterodine Fumarate ER 8 mg, indicating reductions in micturitions with the 8 mg dose showing the greatest decrease.*

FDA Label Image

Fesoterodine-fig2.jpg (Fesoterodine Fig2)

Line chart titled 'Change in Urge Incontinence Episodes per 24 h (Study 1)' showing mean change from baseline in urge incontinence episodes over 12 weeks. It compares placebo, Fesoterodine Fumarate extended-release tablets 4 mg, and 8 mg doses, illustrating decreasing episodes over time with both active treatments versus placebo.*

FDA Label Image

Fesoterodine-fig3.jpg (Fesoterodine Fig3)

Line graph titled 'Change in Number of Micturitions per 24 h (Study 2)' displaying mean change from baseline in number of micturitions over 12 weeks. The x-axis represents weeks (0 to 12) and the y-axis shows the mean change from baseline in micturitions per 24 hours (ranging from 0.0 to -3.0). Three groups are shown: Placebo (dotted line), Fesoterodine Fumarate ER tab 4 mg (triangle markers, dashed line), and Fesoterodine Fumarate ER tab 8 mg (square markers, solid line). Both Fesoterodine groups demonstrate a greater decrease in micturitions compared to placebo over time.*

FDA Label Image

Fesoterodine-fig4.jpg (Fesoterodine Fig4)

A line graph showing mean change from baseline in urge incontinence episodes per 24 hours over 12 weeks for a study with placebo and two doses of Fesoterodine Fumarate extended release tablets (4 mg and 8 mg). The x-axis represents weeks (0 to 12) and the y-axis shows mean change from baseline, with three lines comparing placebo, 4 mg, and 8 mg dose groups.*

FDA Label Image

Fesoterodine-str (Fesoterodine Str)

Chemical structure of fesoterodine fumarate, showing the molecular arrangement of atoms including aromatic rings and functional groups characteristic of this active ingredient.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.